Cancer-Fighting Potential of Bunium Bulbocastanum Seed Extract Against Prostate Tumors

Jenn Hoskins
18th June, 2024

Cancer-Fighting Potential of Bunium Bulbocastanum Seed Extract Against Prostate Tumors

Bunium bulbocastanum

Photo adapted from: Flavien Saboureau / CC BY (Source)

Key Findings

  • The study by the Manipal Academy of Higher Education explored the effects of B. bulbocastanum on prostate cancer in rats
  • The ethyl acetate fraction of B. bulbocastanum showed significant cytotoxic effects on prostate cancer cells in lab tests
  • In treated rats, tumor size and inflammation were reduced, and key cancer markers like PSA and acid phosphatase were significantly lower
Prostate cancer (PCa) continues to be a significant health concern globally, with varying incidence and mortality rates across different regions due to factors such as detection practices, treatment availability, and lifestyle differences[2]. A recent study by the Manipal Academy of Higher Education has explored the therapeutic potential of B. bulbocastanum, a plant known for its cytotoxic, antifungal, and antibacterial properties, in treating PCa[1]. The study investigated the ethyl acetate fraction of B. bulbocastanum and its impact on PC-3 cell lines, a model for prostate cancer. The researchers found that this fraction is rich in phenolic compounds, which are known for their antioxidant properties. In vitro experiments demonstrated significant cytotoxic effects on the PC-3 cell lines, indicating the potential of B. bulbocastanum in inhibiting cancer cell growth. In vivo experiments further supported these findings. The prostate length-to-weight ratio was significantly higher in the ethyl acetate fraction-treated group compared to the disease control group, suggesting a reduction in tumor burden. Histopathological examinations revealed a decrease in inflammation and malignant lesions in the treated group, confirming the antiproliferative efficacy of the ethyl acetate fraction. Serum biochemistry analyses showed that levels of acid phosphatase and prostate-specific antigen (PSA) were significantly lower in the ethyl acetate fraction treatment group than in the disease control group. These biomarkers are commonly used to diagnose and monitor prostate cancer, and their reduction indicates a potential therapeutic effect. Additionally, the study found that malondialdehyde levels, a marker of oxidative stress, were significantly reduced in the ethyl acetate fraction treatment group. Conversely, glutathione levels, which help protect cells from oxidative damage, were considerably increased. These findings suggest that the ethyl acetate fraction of B. bulbocastanum not only has cytotoxic and antiproliferative properties but also enhances the body's antioxidant defense system. The role of oxidative stress in chronic diseases, including cancer, is well-documented. Oxidative stress can lead to chronic inflammation, which in turn can contribute to the development and progression of various chronic diseases such as cancer[3]. By reducing oxidative stress and inflammation, the ethyl acetate fraction of B. bulbocastanum may help mitigate the progression of prostate cancer. This study aligns with previous research highlighting the potential of natural compounds in combating oxidative stress and inflammation. For instance, medicinal plants like Nigella sativa and Curcumin have been shown to reduce lipid peroxidation and improve antioxidant power, making them potential candidates for treating diseases where free radical damage is a key factor[4]. In summary, the study by the Manipal Academy of Higher Education provides promising evidence that the ethyl acetate fraction of B. bulbocastanum could be an effective treatment for prostate cancer. By demonstrating both in vitro and in vivo efficacy, the research supports the potential of this plant extract in reducing tumor growth, inflammation, and oxidative stress, thereby offering a new avenue for PCa treatment.

MedicineHealthBiochem

References

Main Study

1) In Vitro Cytotoxic Activity and In Vivo Antiproliferative Activity of Ethyl Acetate Fraction of Bunium bulbocastanum Seed Against Prostatic Neoplasia

Published 17th June, 2024

https://doi.org/10.1007/s40011-024-01583-7

Related Studies

2) International variation in prostate cancer incidence and mortality rates.

https://doi.org/10.1016/j.eururo.2012.02.054

3) Oxidative stress, inflammation, and cancer: how are they linked?

https://doi.org/10.1016/j.freeradbiomed.2010.09.006

4) A systematic review of the potential herbal sources of future drugs effective in oxidant-related diseases.

Journal: Inflammation & allergy drug targets, Issue: Vol 8, Issue 1, Mar 2009


Related Articles

An unhandled error has occurred. Reload 🗙